Stereotaxis, Inc. (STXS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the interventional laboratory, primarily focusing on Robotic Magnetic Navigation (RMN) for cardiac ablation procedures. The company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $13,961 |
| Gross Margin | $8,280 (59.3%) |
| Operating Loss | $(10,549) |
| Net Loss | $(10,329) |
| Net Loss Attributable to Common Stockholders | $(10,954) |
| Cash and Cash Equivalents (Ending) | $10,491 |
| Working Capital | $11,190 |
| Debt | $0 (No long-term debt) |
| Stockholders' Equity | $12,243 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 14% year-over-year (from $16.3M to $14.0M). System revenue dropped significantly by 44% ($5.0M to $2.8M) due to lower sales volume. Disposables and service revenue remained relatively flat, down 1% ($11.3M to $11.2M).
- Margin Expansion: Despite lower revenue, gross margin percentage improved from 53% to 59%, driven by a favorable shift in product mix toward higher-margin disposables and services.
- Expense Management: Sales and marketing expenses decreased 19% ($6.4M to $5.2M) due to lower headcount and trade-show costs. Research and development expenses increased 16% ($4.1M to $4.8M), partially offset by lower headcount costs compared to the prior year's capitalization of the GenesisX system.
- Cash Flow: Net cash used in operating activities increased to $7.1M from $5.5M, driven by higher operating losses and working capital changes (specifically a $3.0M increase in inventory). Financing activities provided $5.4M, primarily from an at-the-market offering.
Guidance, Outlook, and Risks
- Acquisition of Robocath: On July 7, 2026 (subsequent to the reporting period), the company completed the acquisition of Robocath, a French innovator in mechanical robotic technology, for approximately $20.0 million in cash and stock, with up to $25.0 million in earnout potential. The company expects to fund Robocath's ongoing operations and losses in the coming years.
- Product Transition: The company is transitioning from Johnson & Johnson-supplied catheters (contract ended Dec 31, 2025) to its proprietary MAGiC catheter. While the MAGiC catheter received FDA clearance in January 2026, the transition creates uncertainty regarding procedure volumes and recurring revenue.
- Tariff and Trade Risks: The company faces significant uncertainty regarding U.S. tariffs and trade barriers. While Mexican subassemblies qualify for USMCA exemptions, tariffs on specialty alloys from Europe/Japan and the MAGiC catheter (manufactured in Germany) could impact costs and the economics of the U.S. product launch.
- Liquidity: Management believes existing cash ($10.5M) and proceeds from equity offerings will fund operations through 2026. However, the company expects to incur additional losses and may require further capital raises, which could be dilutive.
- Legal Contingencies: The company has recorded $6.3 million in accrued legal liabilities and an equal amount in insurance receivables related to ongoing litigation.
Investor Verification Checklist
- Robocath Integration: Verify the timeline and cost of integrating Robocath's operations and the specific milestones required to trigger the $25M earnout.
- Catheter Transition: Monitor the ramp-up of MAGiC catheter production and sales to ensure it successfully replaces J&J volumes without disrupting recurring revenue.
- Tariff Impact: Assess the final impact of Section 301 and other tariffs on the cost of the MAGiC catheter and the feasibility of the U.S. launch.
- Cash Burn Rate: Track the monthly cash burn rate given the increased R&D spend and the funding requirements for Robocath.
- System Sales Pipeline: Evaluate the backlog and sales pipeline for RMN systems, as system revenue is currently depressed and critical for long-term growth.